Home Medical OncologyQuestion

Would you offer neoadjuvant chemotherapy to a patient with muscle-invasive enteric adenocarcinoma of the bladder?

1

Join the Discussion

Discuss the cases and questions guidelines don't cover.

Related Questions

What is your preferred treatment for a patient with refractory metastatic upper tract urothelial carcinoma previously treated with adjuvant gemcitabine/cisplatin, enfortumab vedotin + pembrolizumab, docetaxel and sacituzumab govitecan?

Would you consider utilizing pembrolizumab/enfortumab as a bladder preservation approach in patients with MIBC?

Which patients are you utilizing subcutaneous PD-1/L1 inhibitors instead of the intravenous formulation?

How do the results of KEYNOTE-B15/EV-304 influence your preferred treatment for cisplatin eligible MIBC?

In patients with muscle-invasive bladder cancer, in what clinical scenarios would you consider neoadjuvant cisplatin-based therapy in light of emerging data on enfortumab vedotin plus pembrolizumab?

Evidence Meets Expertise

For Physicians

Mednet AI
Community

Company

About
Careers
Publications
Blog

Support

FAQs
Code of Conduct
AI Community Guidelines
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.